AP3286A - Glucagon analogues - Google Patents

Glucagon analogues

Info

Publication number: AP3286A
Authority: AP; ARIPO
Prior art keywords: glucagon analogues; glucagon; analogues
Prior art date: 2010-06-23

Application number

AP2013006669A

Other languages

English (en)

Other versions

AP2013006669A0 (en

Inventor

Eddi Meier

Ditte Riber

Jens Rosengren Daugaard

Original Assignee

Zealand Pharma As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-06-23

Filing date

2011-06-23

Publication date

2015-05-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44630045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP3286(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-06-23 Application filed by Zealand Pharma As filed Critical Zealand Pharma As

2013-01-31 Publication of AP2013006669A0 publication Critical patent/AP2013006669A0/xx

2015-05-31 Application granted granted Critical

2015-05-31 Publication of AP3286A publication Critical patent/AP3286A/xx

Links

MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Toxicology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Cardiology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Obesity (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AP2013006669A 2010-06-23 2011-06-23 Glucagon analogues AP3286A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DKPA201000550		2010-06-23
US35862310P	2010-06-25	2010-06-25
PCT/DK2011/000067 WO2011160630A2 (en)	2010-06-23	2011-06-23	Glucagon analogues

Publications (2)

Publication Number	Publication Date
AP2013006669A0 AP2013006669A0 (en)	2013-01-31
AP3286A true AP3286A (en)	2015-05-31

Family

ID=44630045

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2013006669A AP3286A (en)	2010-06-23	2011-06-23	Glucagon analogues

Country Status (23)

Country	Link
US (2)	US9403894B2 (xx)
EP (1)	EP2585481B1 (xx)
JP (1)	JP5937582B2 (xx)
KR (1)	KR20130086339A (xx)
CN (1)	CN103038250A (xx)
AP (1)	AP3286A (xx)
AR (1)	AR081975A1 (xx)
AU (1)	AU2011269427A1 (xx)
BR (1)	BR112012033227A2 (xx)
CA (1)	CA2802889A1 (xx)
CL (1)	CL2012003643A1 (xx)
CO (1)	CO6660484A2 (xx)
EA (1)	EA201291233A1 (xx)
EC (1)	ECSP12012351A (xx)
MX (1)	MX2012014774A (xx)
NZ (1)	NZ604033A (xx)
PE (1)	PE20130326A1 (xx)
PH (1)	PH12012502461A1 (xx)
SG (1)	SG186276A1 (xx)
TN (1)	TN2012000567A1 (xx)
TW (1)	TW201202265A (xx)
UY (1)	UY33462A (xx)
WO (1)	WO2011160630A2 (xx)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2607150C (en)	2005-05-04	2014-08-05	Bjarne Due Larsen	Glucagon-like-peptide-2 (glp-2) analogues
CA2669806C (en)	2006-11-08	2018-10-02	Zealand Pharma A/S	Selective glucagon-like-peptide-2 (glp-2) analogues
WO2010070253A1 (en)	2008-12-15	2010-06-24	Zealand Pharma A/S	Glucagon analogues
US8685919B2 (en)	2008-12-15	2014-04-01	Zealand Pharma A/S	Glucagon analogues
MX2011006314A (es)	2008-12-15	2011-09-22	Zealand Pharma As	Analogos de glucagon.
CA2747197A1 (en)	2008-12-15	2010-06-24	Zealand Pharma A/S	Glucagon analogues
PT2454282E (pt)	2009-07-13	2015-06-23	Zealand Pharma As	Análogos de glucagão acilados
UY33462A (es)	2010-06-23	2012-01-31	Zealand Pharma As	Analogos de glucagon
US9169310B2 (en)	2010-06-24	2015-10-27	Zealand Pharma A/S	Glucagon analogues
MX2013008005A (es) *	2011-01-20	2013-08-21	Zealand Pharma As	Combinacion de analogos de glucagon acilados con analogos de insulina.
JP6352806B2 (ja)	2011-09-23	2018-07-04	ノヴォノルディスクアー／エス	新規のグルカゴン類似体
AP2014007797A0 (en) *	2011-12-23	2014-07-31	Boehringer Ingelheim Int	Glucagon analogues
JP6228187B2 (ja)	2012-05-03	2017-11-08	ジーランドファーマアクティーゼルスカブ	Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
EA028929B1 (ru)	2012-05-03	2018-01-31	Зилэнд Фарма А/С	Аналоги глюкагоноподобного пептида-2 (glp-2)
JP2015525226A (ja)	2012-06-14	2015-09-03	サノフイ	エキセンディン−４ペプチドアナログ
JP6534927B2 (ja)	2012-07-23	2019-06-26	ジーランドファーマアクティーゼルスカブ	グルカゴン類似体
GB2505941A (en) *	2012-09-17	2014-03-19	Imp Innovations Ltd	Peptide analogues of glucagon for the treatment of obesity and diabetes
TWI608013B (zh) *	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
WO2014041375A1 (en)	2012-09-17	2014-03-20	Imperial Innovations Limited	Peptide analogues of glucagon and glp1
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
LT2934568T (lt)	2012-12-21	2018-02-12	Sanofi	Dvigubi glp1/gip arba trigubi glp/gip/gliukagono agonistai
CN105102427B (zh)	2013-03-21	2018-09-07	赛诺菲-安万特德国有限公司	含有环状酰亚胺的肽产物的合成
HUE034308T2 (en)	2013-03-21	2018-02-28	Sanofi Aventis Deutschland	Preparation of hydantoin-containing peptide products
AR095986A1 (es)	2013-04-03	2015-11-25	Sanofi Sa	Proteínas modificadas que regulan glucosa en sangre con perfil alterado de actividad farmacológica y preparación de las mismas
CA2909581A1 (en)	2013-04-18	2014-10-23	Novo Nordisk A/S	Stable, protracted glp-1/glucagon receptor co-agonists for medical use
PE20160683A1 (es)	2013-10-17	2016-07-21	Zealand Pharma As	Analogos de glucagon acilados
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
MX2016005556A (es) *	2013-11-06	2016-07-15	Zealand Pharma As	Compuestos agonistas duales de gip-glp-1 y procedimientos.
US10131702B2 (en)	2013-11-06	2018-11-20	Zealand Pharma A/S	Glucagon-GLP-1-GIP triple agonist compounds
WO2015086729A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/gip receptor agonists
EP3080152A1 (en)	2013-12-13	2016-10-19	Sanofi	Non-acylated exendin-4 peptide analogues
EP3080155A1 (en)	2013-12-13	2016-10-19	Sanofi	Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
TW201609797A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／升糖素受體促效劑
EP3080150B1 (en)	2013-12-13	2018-08-01	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US10570184B2 (en)	2014-06-04	2020-02-25	Novo Nordisk A/S	GLP-1/glucagon receptor co-agonists for medical use
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
ES2883345T3 (es)	2014-10-29	2021-12-07	Zealand Pharma As	Compuestos agonistas del GIP y métodos
US10213487B2 (en)	2015-02-17	2019-02-26	Eli Lilly And Company	Nasal powder formulation for treatment of hypoglycemia
CA2979950A1 (en)	2015-03-18	2016-09-22	Zealand Pharma A/S	Amylin analogues
WO2016168388A2 (en)	2015-04-14	2016-10-20	Palatin Technologies, Inc.	Therapies for obesity, diabetes and related indications
AU2016247499B2 (en)	2015-04-16	2020-09-03	Zealand Pharma A/S	Acylated glucagon analogue
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198628A1 (en)	2015-06-12	2016-12-15	Sanofi	Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
WO2016198624A1 (en)	2015-06-12	2016-12-15	Sanofi	Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
GB2566228A (en)	2016-06-09	2019-03-06	AmideBio LLC	Glucagon analogs and methods of use thereof
MA45843B1 (fr)	2016-08-05	2021-06-30	Boehringer Ingelheim Int	Dérivés d'oxadiazolopyridine utilisés comme inhibiteurs de la ghréline o-acyl transférase (chèvre)
AR109514A1 (es)	2016-09-09	2018-12-19	Zealand Pharma As	Análogos de amilina
KR101887577B1 (ko) *	2016-10-19	2018-09-10	(주)케어젠	항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
TW201832783A (zh)	2016-12-02	2018-09-16	法商賽諾菲公司	包含ｇｌｐ－１／胰高血糖素雙重激動劑、連接子和透明質酸的接合物
BR112019010624A2 (pt)	2016-12-09	2019-10-22	Zealand Pharma As	agonistas duplos de glp-1/glp-2 acilados e composição
KR102504200B1 (ko)	2017-06-16	2023-02-28	질랜드 파마 에이/에스	글루카곤-유사-펩티드-2 (glp-2) 유사체의 투여를 위한 용량요법
HRP20240371T1 (hr) *	2017-08-16	2024-06-07	Dong-A St Co., Ltd	Peptidni analog aciliranog oksintomodulina
WO2019149657A1 (en)	2018-02-02	2019-08-08	Boehringer Ingelheim International Gmbh	Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors
EP3746449B1 (en)	2018-02-02	2022-03-30	Boehringer Ingelheim International GmbH	Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
EA202091804A1 (ru)	2018-02-02	2020-12-24	Бёрингер Ингельхайм Интернациональ Гмбх	Гетероциклил-замещенные оксадиазолопиридиновые производные для применения в качестве ингибиторов грелин-о-ацилтрансферазы (goat)
EP3746443B1 (en)	2018-02-02	2022-07-06	Boehringer Ingelheim International GmbH	Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
CA3096493A1 (en) *	2018-04-10	2019-10-17	Sanofi-Aventis Deutschland Gmbh	Method for cleavage of solid phase-bound peptides from the solid phase
BR112020020647A2 (pt)	2018-04-10	2021-02-23	Sanofi-Aventis Deutschland Gmbh	síntese de lixisenatida com capeamento
WO2020125744A1 (zh)	2018-12-21	2020-06-25	江苏恒瑞医药股份有限公司	双特异性蛋白
TWI771669B (zh)	2019-04-26	2022-07-21	美商美國禮來大藥廠	製備穩定胜肽調配物之方法
EP4015528A4 (en) *	2019-08-13	2023-09-20	Anygen Co., Ltd.	EXENATIDE ANALOG AND ITS USE
CN114641303A (zh)	2019-11-11	2022-06-17	勃林格殷格翰国际有限公司	Npy2受体激动剂
HUE069479T2 (hu)	2020-05-22	2025-04-28	Boehringer Ingelheim Int	Alkil 7-amino-5-metil-[1,2,5]-oxadiazolo[3,4-b]piridin-karboxilát folyamatos elõállítási eljárása
EP4153599B1 (en)	2020-05-22	2024-03-13	Boehringer Ingelheim International GmbH	Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
CN113292646B (zh) *	2020-05-29	2022-05-13	东莞云璟生物技术有限公司	Glp-1/胰高血糖素双重激动剂融合蛋白
CR20230074A (es)	2020-08-07	2023-04-19	Boehringer Ingelheim Int	Agonistas del receptor npy2 solubles
WO2024165571A2 (en)	2023-02-06	2024-08-15	E-Therapeutics Plc	Inhibitors of expression and/or function
WO2025125576A2 (en)	2023-12-15	2025-06-19	E-Therapeutics Plc	Inhibitors of expression and/or function
WO2025133348A1 (en)	2023-12-22	2025-06-26	E-Therapeutics Plc	Inhibitors of expression and/or function
EP4686757A1 (en)	2024-07-31	2026-02-04	e-therapeutics PLC	Inhibitors of expression and/or function
WO2025196502A1 (en)	2024-03-20	2025-09-25	North Carolina Agricultural & Technical State University	Choline kinase inhibitors as a therapeutic treatment for obesity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008152403A1 (en) *	2007-06-15	2008-12-18	Zealand Pharma A/S	Glucagon analogues
WO2010070255A1 (en) *	2008-12-15	2010-06-24	Zealand Pharma A/S	Glucagon analogues
WO2011088837A1 (en) *	2010-01-20	2011-07-28	Zealand Pharma A/S	Treatment of cardiac conditions

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ202757A (en)	1981-12-23	1985-11-08	Novo Industri As	Peptides and medicaments
HU227021B1 (en)	1996-08-30	2010-05-28	Novo Nordisk As	Glp-1 derivatives
NZ334595A (en)	1996-09-09	2000-08-25	Zealand Pharmaceuticals As	Peptide prodrugs containing an alpha-hydroxyacid linker that have increased stability against enzymatic cleavage
AU723268B2 (en)	1996-09-09	2000-08-24	Zealand Pharma A/S	Improved solid-phase peptide synthesis and agent for use in such synthesis
EP1066314B1 (en)	1997-11-14	2007-12-26	Amylin Pharmaceuticals, Inc.	Novel exendin agonist compounds
WO1999046283A1 (en)	1998-03-09	1999-09-16	Zealand Pharmaceuticals A/S	Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
NZ511931A (en)	1998-12-07	2004-01-30	Sod Conseils Rech Applic	Analogues of glucagon like peptide-1
US6451987B1 (en)	1999-03-15	2002-09-17	Novo Nordisk A/S	Ion exchange chromatography of proteins and peptides
RU2001128068A (ru)	1999-03-17	2004-02-20	Ново Нордиск А/С (DK)	Способ ацилирования пептидов и новые ацилирующие агенты
EP1076066A1 (en)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
GB0121709D0 (en)	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
WO2003053460A1 (en)	2001-12-19	2003-07-03	Eli Lilly And Company	Crystalline compositions for controlling blood glucose
SK2432004A3 (sk)	2001-12-20	2005-04-01	Eli Lilly And Company	Inzulínová zlúčenina s protrahovaným účinkom
GB0300571D0 (en)	2003-01-10	2003-02-12	Imp College Innovations Ltd	Modification of feeding behaviour
KR20050121748A (ko)	2003-04-29	2005-12-27	일라이 릴리 앤드 캄파니	연장된 시간 작용을 갖는 인슐린 유사체
KR101349808B1 (ko)	2005-06-13	2014-02-13	임페리얼 이노베이션스 리미티드	섭취행동에 관한 신규 화합물들 및 이들의 효능
US20090202497A1 (en)	2005-08-23	2009-08-13	The General Hospital Corporation	Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
ES2507098T3 (es)	2005-11-07	2014-10-14	Indiana University Research And Technology Corporation	Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas
WO2007081824A2 (en)	2006-01-06	2007-07-19	Case Western Reserve University	Fibrillation resistant proteins
AU2007221366B2 (en)	2006-02-22	2012-08-23	Msd Italia S.R.L.	Oxyntomodulin derivatives
USRE47123E1 (en)	2006-07-18	2018-11-13	Sanofi	EPHA2 receptor antagonist antibodies
WO2008043033A2 (en)	2006-10-04	2008-04-10	Case Western Reserve University	Fibrillation-resistant insulin and insulin analogues
TWI428346B (zh)	2006-12-13	2014-03-01	Imp Innovations Ltd	新穎化合物及其等對進食行為影響
KR20150116465A (ko)	2007-02-15	2015-10-15	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	글루카곤/ｇｌｐ-1 수용체 공동-항진물질
EP2025684A1 (en)	2007-08-15	2009-02-18	Zealand Pharma A/S	Glucagon analogues
NZ603812A (en)	2007-11-20	2014-06-27	Ambrx Inc	Modified insulin polypeptides and their uses
AU2009203810B2 (en)	2008-01-09	2013-07-25	Sanofi-Aventis Deutschland Gmbh	Novel insulin derivatives having an extremely delayed time-action profile
DE102008003566A1 (de)	2008-01-09	2009-07-16	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
CA2711749A1 (en)	2008-01-09	2009-07-16	Sanofi-Aventis Deutschland Gmbh	Novel insulin derivatives having an extremely delayed time-action profile
DE102008003568A1 (de)	2008-01-09	2009-07-16	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
WO2009129250A2 (en)	2008-04-14	2009-10-22	Case Western Reserve University	Meal-time insulin analogues of enhanced stability
CN102065885A (zh)	2008-04-22	2011-05-18	卡斯西部储备大学	同种型特异性的胰岛素类似物
TWI451876B (zh)	2008-06-13	2014-09-11	Lilly Co Eli	聚乙二醇化之離脯胰島素化合物
US8546327B2 (en)	2008-06-17	2013-10-01	Indiana University Research And Technology Corporation	Glucagon/GLP-1 receptor co-agonists
JP5753779B2 (ja)	2008-06-17	2015-07-22	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
PL219335B1 (pl)	2008-07-04	2015-04-30	Inst Biotechnologii I Antybiotyków	Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
CA2732439A1 (en)	2008-07-31	2010-02-04	Case Western Reserve University	Halogen-stabilized insulin
MX2011006314A (es)	2008-12-15	2011-09-22	Zealand Pharma As	Analogos de glucagon.
US8685919B2 (en) *	2008-12-15	2014-04-01	Zealand Pharma A/S	Glucagon analogues
WO2010070253A1 (en)	2008-12-15	2010-06-24	Zealand Pharma A/S	Glucagon analogues
CN102256992B (zh)	2008-12-19	2015-04-22	印第安纳大学研究及科技有限公司	胰岛素类似物
JP5755566B2 (ja)	2008-12-19	2015-07-29	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	アミド系インスリンプロドラッグ
CN101519446A (zh)	2009-03-31	2009-09-02	上海一就生物医药有限公司	一种重组人胰岛素及其类似物的制备方法
PT2454282E (pt)	2009-07-13	2015-06-23	Zealand Pharma As	Análogos de glucagão acilados
UY33462A (es)	2010-06-23	2012-01-31	Zealand Pharma As	Analogos de glucagon
US9169310B2 (en)	2010-06-24	2015-10-27	Zealand Pharma A/S	Glucagon analogues
MX2013008005A (es)	2011-01-20	2013-08-21	Zealand Pharma As	Combinacion de analogos de glucagon acilados con analogos de insulina.
AP2014007797A0 (en)	2011-12-23	2014-07-31	Boehringer Ingelheim Int	Glucagon analogues
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
PE20160683A1 (es)	2013-10-17	2016-07-21	Zealand Pharma As	Analogos de glucagon acilados
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues

2011
- 2011-06-22 UY UY0001033462A patent/UY33462A/es not_active Application Discontinuation
- 2011-06-22 AR ARP110102166A patent/AR081975A1/es unknown
- 2011-06-23 BR BR112012033227A patent/BR112012033227A2/pt not_active IP Right Cessation
- 2011-06-23 US US13/702,841 patent/US9403894B2/en not_active Expired - Fee Related
- 2011-06-23 WO PCT/DK2011/000067 patent/WO2011160630A2/en not_active Ceased
- 2011-06-23 KR KR1020137000529A patent/KR20130086339A/ko not_active Withdrawn
- 2011-06-23 CA CA2802889A patent/CA2802889A1/en not_active Abandoned
- 2011-06-23 MX MX2012014774A patent/MX2012014774A/es not_active Application Discontinuation
- 2011-06-23 PE PE2012002434A patent/PE20130326A1/es not_active Application Discontinuation
- 2011-06-23 PH PH1/2012/502461A patent/PH12012502461A1/en unknown
- 2011-06-23 CN CN2011800305150A patent/CN103038250A/zh active Pending
- 2011-06-23 NZ NZ604033A patent/NZ604033A/en not_active IP Right Cessation
- 2011-06-23 AP AP2013006669A patent/AP3286A/xx active
- 2011-06-23 SG SG2012090890A patent/SG186276A1/en unknown
- 2011-06-23 AU AU2011269427A patent/AU2011269427A1/en not_active Abandoned
- 2011-06-23 EA EA201291233A patent/EA201291233A1/ru unknown
- 2011-06-23 TW TW100122081A patent/TW201202265A/zh unknown
- 2011-06-23 EP EP11741513.3A patent/EP2585481B1/en active Active
- 2011-06-23 JP JP2013515697A patent/JP5937582B2/ja not_active Expired - Fee Related
2012
- 2012-11-30 TN TNP2012000567A patent/TN2012000567A1/en unknown
- 2012-12-20 EC ECSP12012351 patent/ECSP12012351A/es unknown
- 2012-12-21 CL CL2012003643A patent/CL2012003643A1/es unknown
- 2012-12-21 CO CO12232550A patent/CO6660484A2/es unknown
2016
- 2016-06-27 US US15/194,025 patent/US20160304576A1/en not_active Abandoned

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008152403A1 (en) *	2007-06-15	2008-12-18	Zealand Pharma A/S	Glucagon analogues
WO2010070255A1 (en) *	2008-12-15	2010-06-24	Zealand Pharma A/S	Glucagon analogues
WO2011088837A1 (en) *	2010-01-20	2011-07-28	Zealand Pharma A/S	Treatment of cardiac conditions

Also Published As

Publication number	Publication date
KR20130086339A (ko)	2013-08-01
MX2012014774A (es)	2013-01-29
EP2585481B1 (en)	2015-08-19
SG186276A1 (en)	2013-01-30
JP2013534919A (ja)	2013-09-09
UY33462A (es)	2012-01-31
PE20130326A1 (es)	2013-03-17
AR081975A1 (es)	2012-10-31
TW201202265A (en)	2012-01-16
PH12012502461A1 (en)	2013-02-18
ECSP12012351A (es)	2013-01-31
CO6660484A2 (es)	2013-04-30
CL2012003643A1 (es)	2013-08-02
US9403894B2 (en)	2016-08-02
JP5937582B2 (ja)	2016-06-22
EA201291233A1 (ru)	2013-07-30
BR112012033227A2 (pt)	2017-06-20
US20130157935A1 (en)	2013-06-20
TN2012000567A1 (en)	2014-04-01
AP2013006669A0 (en)	2013-01-31
AU2011269427A1 (en)	2012-12-20
NZ604033A (en)	2014-12-24
WO2011160630A2 (en)	2011-12-29
EP2585481A2 (en)	2013-05-01
US20160304576A1 (en)	2016-10-20
CA2802889A1 (en)	2011-12-29
WO2011160630A3 (en)	2012-02-16
CN103038250A (zh)	2013-04-10

Publication	Publication Date	Title
AP3286A (en)	2015-05-31	Glucagon analogues
AP2013006671A0 (en)	2013-01-31	Glucagon analogues
ZA201206838B (en)	2013-06-26	Novel glucagon analogues
IL232800A0 (en)	2014-07-31	Glucagon analog
ZA201702364B (en)	2019-05-29	Glucagon analogues
IL231199A0 (en)	2014-04-30	New analogs of glucagon
IL237518A0 (en)	2015-04-30	Glucagon analog
ZA201306514B (en)	2014-05-28	Novel glucagon analogues
IL213479A0 (en)	2011-07-31	Glucagon analogues
IL213478A0 (en)	2011-07-31	Glucagon analogues
IL213480A0 (en)	2011-07-31	Glucagon analogues
IL213477A0 (en)	2011-07-31	Glucagon analogues
SG10201501305QA (en)	2015-04-29	Scaffolding
EP2576612A4 (en)	2014-07-09	INSULIN ANALOG
GB2479441B (en)	2017-08-23	Coelenterazine analogues
GB201018245D0 (en)	2010-12-15	Platform slot recovery
HUP1100726A2 (en)	2012-09-28	Component
GB201004491D0 (en)	2010-05-05	Quinazoline analogues
HK1177622A (en)	2013-08-23	Glucagon analogues
HK1177621A (en)	2013-08-23	Glucagon analogues
GB201018136D0 (en)	2010-12-08	Project
AU337827S (en)	2011-07-26	Ladder
ZA201109183B (en)	2012-08-29	Prop